For the very first time, a new study has demonstrated that it could be possible to shield against cerebral cognitive and memory decline in mice by using gene therapy to boost brain levels of a protein named Klotho.
The study’s findings are important as they’re the first to demonstrate that injecting a single dose of Klotho-promoting gene therapy to the central nervous system (CNS) of young mice averted age-related cognitive decline when they reached old age.
The researchers also discovered that the therapy even shielded against “age-dependent cognitive decrease when mice were treated in old ages.”
The group expects that the findings will advance research and development of new therapies for neurodegenerative diseases like dementia according to Klotho, which has already been known for its “neuroprotective” function.
Klotho aging and gene
The new research builds on past work by a number of the identical group members, where they revealed that the Klotho gene can help to restrain circadian mechanisms.
In that earlier study, they discovered that if over-expressed, Klotho increases endurance, and as soon as it’s blocked, it rates up decrease in learning and memory.
To their new analysis, the group used gene therapy to boost manifestation of Klotho to increase creation of the related protein.
“The treatment is based on an gain in the amounts of the protein in the brain with an adeno-associated viral vector (AAV),” clarifies Dr. Miguel Chillón, a researcher in biochemistry and molecular biology in both study centres.
The viruses have been altered so that they can’t induce disease and may carry the compulsory gene-altering substance into cells.
Researchers have been exploring AAVs for 55 decades, and their capacity as a gene therapy for certain kinds of hereditary disorders show much promise in trials.